Sprinklr's (NYSE:CXM) Q1 Sales Top Estimates, Quarterly Revenue Guidance Slightly Exceeds Expectations
Is now the time to buy Sprinklr? Find out in our full research report.
Revenue: $205.5 million vs analyst estimates of $201.8 million (4.9% year-on-year growth, 1.8% beat)
Adjusted EPS: $0.12 vs analyst estimates of $0.10 (21.6% beat)
Adjusted Operating Income: $36.74 million vs analyst estimates of $31.9 million (17.9% margin, 15.2% beat)
The company slightly lifted its revenue guidance for the full year to $826 million at the midpoint from $822.5 million
Management raised its full-year Adjusted EPS guidance to $0.40 at the midpoint, a 2.6% increase
Operating Margin: -0.9%, down from 2.9% in the same quarter last year
Free Cash Flow Margin: 39.3%, up from 0.8% in the previous quarter
Market Capitalization: $2.20 billion
'Our Q1 results reflect solid progress in our transformation to better serve our customers and partners. We are deeply focused on improving our execution and delivering business value to the brands we serve with our AI-native CXM platform. We also generated record free cash flow in the quarter,' said Rory Read, Sprinklr President and CEO.
Initially focused only on social media management, Sprinklr (NYSE: CXM) is a leading provider of unified customer experience management software.
Reviewing a company's long-term sales performance reveals insights into its quality. Any business can have short-term success, but a top-tier one grows for years. Over the last three years, Sprinklr grew its sales at a 15.3% compounded annual growth rate. Although this growth is acceptable on an absolute basis, it fell slightly short of our standards for the software sector, which enjoys a number of secular tailwinds.
This quarter, Sprinklr reported modest year-on-year revenue growth of 4.9% but beat Wall Street's estimates by 1.8%. Company management is currently guiding for a 4.2% year-on-year increase in sales next quarter.
Looking further ahead, sell-side analysts expect revenue to grow 2.8% over the next 12 months, a deceleration versus the last three years. This projection doesn't excite us and implies its products and services will see some demand headwinds.
Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.
The customer acquisition cost (CAC) payback period measures the months a company needs to recoup the money spent on acquiring a new customer. This metric helps assess how quickly a business can break even on its sales and marketing investments.
It's relatively expensive for Sprinklr to acquire new customers as its CAC payback period checked in at 168.9 months this quarter. The company's slow recovery of its sales and marketing expenses indicates it operates in a highly competitive market and must invest to stand out, even if the return on that investment is low.
We were impressed by how Sprinklr raised its full-year revenue and EPS guidance, which blew past analysts' expectations. We were also glad its revenue, EPS, and adjusted operating income exceeded Wall Street's estimates. Overall, we think this was a solid "beat-and-raise" quarter. The stock traded up 3.9% to $8.89 immediately following the results.
Sprinklr had an encouraging quarter, but one earnings result doesn't necessarily make the stock a buy. Let's see if this is a good investment. The latest quarter does matter, but not nearly as much as longer-term fundamentals and valuation, when deciding if the stock is a buy. We cover that in our actionable full research report which you can read here, it's free.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
27 minutes ago
- Forbes
What's Happening With ORCL Stock?
CHINA - 2025/06/15: In this photo illustration, the logo of Oracle is seen displayed on the screen ... More of a smartphone. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images) With a 43% increase year-to-date (YTD), Oracle stock (NYSE:ORCL) has performed significantly better than the broader S&P 500 index, which has risen by 7%. This outperformance can be partly linked to the increasing demand for Oracle's cloud services amidst the AI boom. The company's Cloud Infrastructure (OCI) and Cloud Application (SaaS) revenues have been steadily growing at impressive rates. Even when considering a slightly longer timeframe, ORCL stock has skyrocketed an astonishing 3x since early 2023, propelled by three key factors: We will delve into these factors in greater detail. Although ORCL stock has provided substantial returns, those in search of growth with lower volatility than individual stocks might consider the High Quality portfolio, which has surpassed the S&P 500 with returns exceeding 91% since its inception. Additionally, refer to – SOUN Stock To $20? What's Behind The Revenue Growth? Oracle has shown robust fundamental performance with a 35% increase in revenue, which has expanded from $42 billion in 2022 to $57 billion in the trailing twelve months. The company's impressive advancement is primarily driven by the increasing demand for its Cloud Infrastructure (OCI), significantly fueled by the Artificial Intelligence (AI) boom. What's Driving The Valuation Higher For Oracle Stock? Oracle's stock has undergone a significant surge in valuation multiples, with its price-to-sales (P/S) ratio escalating 127% from 5.2x in 2022 to 11.8x presently. Several critical factors are propelling this continued growth: But What Next? Is ORCL Stock A Buy At $235? Currently trading at around $235, Oracle (ORCL) stock appears to be highly valued. Its price-to-sales (P/S) multiple is at 11.7x, significantly above its four-year average of 6.5x. Likewise, the stock's trailing adjusted earnings multiple is 54 times, considerably higher than its average price-to-earnings (P/E) ratio of 32 times over the previous four years. While Oracle is undoubtedly positioned to gain from the growing adoption of AI and the increased demand for cloud infrastructure, these favorable elements appear to be fully accounted for in the existing stock price. See Oracle's Valuation Ratios for more context. But There Are Risks Despite the positive outlook, there are significant risks to consider. During the inflation-driven downturn of 2022, ORCL stock fell by 41%, dropping from a peak of $104 in December 2021 to $61 by September 2022. In comparison, the S&P 500 experienced a smaller decline of 25%. Although ORCL recovered to its pre-crisis peak by May 2023, a similar sell-off took place earlier this year due to trade war fears, with ORCL plunging nearly 34%, which was steeper than the 19% drop for the S&P 500. More information is available in our Buy or Sell Oracle Stock dashboard. In addition to macroeconomic and geopolitical risks, Oracle faces internal challenges, particularly concerning its significant capital expenditures. From just $4.5 billion in 2022, the company's capital expenditures soared to over $21 billion in fiscal 2025 and are projected to exceed $25 billion this year. A critical question remains: What happens if these large-scale investments do not yield the anticipated returns? We now implement a risk assessment framework as we construct the 30-stock Trefis High Quality (HQ) Portfolio, which has a proven record of comfortably outperforming the S&P 500 over the last 4-year period. What is the reason? As a collective, HQ Portfolio stocks have yielded superior returns with reduced risk compared to the benchmark index, providing a less volatile experience, as reflected in HQ Portfolio performance metrics.
Forbes
27 minutes ago
- Forbes
MSFT Stock To $1,000?
The OpenAI logo appears on a smartphone screen and the Microsoft logo on a laptop screen as the ... More background in Athens, Greece, on July 4, 2025. Microsoft cuts up to 9,000 more jobs as it invests in AI. (Photo by Nikolas Kokovlis/NurPhoto via Getty Images) Microsoft's stock (NASDAQ:MSFT) has already achieved remarkable gains, increasing over 2x from $235 in early 2023 to about $500 now. What factors could drive the stock to double from its current value over the next few years? The answer is found in Azure and AI – the main growth engine for Microsoft. The company's AI strategy is yielding tangible results, with notable uptake of its AI-driven features across its product offerings. This momentum, especially in its cloud computing sector, positions Microsoft for significant future expansion as businesses progressively adopt AI solutions in their operations. On another note, if you seek an upside with a smoother experience than a single stock, you might explore the High Quality portfolio, which has outperformed the S&P 500, garnering >91% returns since its inception. Additionally, check out – SOUN Stock To $20? Microsoft is making a significant investment in its AI infrastructure, with capital expenditures expected to rise from approximately $44 billion in 2024 to over $80 billion in 2025. This considerable investment is largely driven by the growing demands of artificial intelligence. Azure is the primary beneficiary of this investment in AI infrastructure, experiencing over 30% growth that is anticipated to persist in the near future. However, Microsoft's integration of AI extends well beyond Azure. Hundreds of thousands of customers are already utilizing Microsoft 365 Copilot to transform their daily workflows. This represents a major transition for Microsoft, shifting from the sale of traditional software licenses to providing AI-driven productivity improvements, which command premium pricing and encourage deeper customer dependence. For instance, more than 230,000 organizations—including 90% of the Fortune 500—have already embraced Copilot Studio to create AI agents, indicating Microsoft's successful shift from pilot projects to widespread enterprise implementation. Revenue Acceleration Microsoft's Intelligent Cloud segment serves as the company's foremost revenue driver, producing roughly $105 billion in 2024 with impressive 20% growth. This segment is Microsoft's fastest-growing and highest-margin area, benefiting from its unique status as both a cloud infrastructure provider and a leader in enterprise software. The incorporation of AI capabilities into Azure services further increases its value, while strong enterprise relationships ensure customer loyalty and opportunities for upselling. While Azure's rapid growth garners significant attention, Microsoft's Productivity and Business Processes segment provides an essential foundation. This segment, which includes Microsoft 365, generated $78 billion in 2024, delivering stable, recurring income. This dependable revenue source allows Microsoft to finance investments in high-growth fields such as AI and cloud services. The 82.5 million Office 365 subscriptions, an increase of 10% year-over-year, highlight the stickiness of this business. With total annual revenues exceeding $245 billion, this stable base enables Microsoft to aggressively invest in AI and cloud infrastructure while maintaining strong profitability across its varied business portfolio. Path To 2x Growth For Microsoft's stock to double, the company must maintain its impressive growth, predominantly driven by its strategic leadership in AI and cloud computing. This growth will likely be propelled by the increasing adoption of AI across its Azure platform and the robust monetization of its AI-driven software, especially Microsoft 365 Copilot. Examining the figures, we estimate Microsoft's revenues will surpass $405 billion within the next four years, with adjusted earnings exceeding $20 per share. Currently trading around $500, MSFT stock is valued at about 14 times its trailing revenues. Although this is slightly higher than its four-year average price-to-sales (P/S) ratio of over 12 times, the substantial growth in Azure and Copilot may justify a premium. If Azure sustains its remarkable 30%+ growth rate, the accelerated revenue could merit even higher valuation multiples. Additionally, AI services often yield higher margins than traditional cloud infrastructure. As AI becomes a more significant contributor to Microsoft's revenue, operational leverage could lead to considerable profit growth. If Microsoft establishes a clear lead in enterprise AI, mirroring its historical dominance in productivity software, investors might attribute a lasting premium valuation to the stock. Even a minor increase in the P/S ratio to 18 times could push the stock beyond $1,000 within the next four years. The combination of growing revenues across all segments and improved profitability stemming from AI efficiencies could substantially enhance investor confidence in Microsoft. As the company showcases its ability to monetize significant AI investments while preserving market leadership, investors may begin to apply premium valuation multiples typically reserved for high-growth technology firms. This multiple expansion, coupled with fundamental business growth, provides a mathematical foundation for the stock to double. This outcome relies on both sustained revenue growth and a reevaluation of Microsoft's long-term earnings potential within the AI economy. Potential Risks to Growth While Microsoft's trajectory appears optimistic, a number of factors could impede the stock from doubling. The primary concern is the normalization of AI spending. Companies might become more cautious about initiating new Azure projects, implying that the current rate of AI investment may not be sustainable over the long term. Additionally, competition from Google, Amazon, and emerging competitors could also challenge Microsoft's pricing power in the AI market and its ability to gain market share. High-interest rates could render growth stocks like Microsoft less attractive compared to fixed-income alternatives. In summary, investors considering a position in Microsoft should also account for these risks. Now, we implement a risk assessment framework while developing the Trefis High Quality (HQ) Portfolio, which, consisting of 30 stocks, has a record of significantly outperforming the S&P 500 over the last four years. Why is that? Collectively, HQ Portfolio stocks have delivered superior returns with lower risk compared to the benchmark index; experiencing less volatility, as shown in HQ Portfolio performance metrics.
Geek Wire
44 minutes ago
- Geek Wire
Microsoft and the microbiome: Viome works with tech giant to optimize AI for molecular health
Naveen Jain, Viome CEO and founder, worked at Microsoft early in his career. (Viome Photo) Viome, a life sciences startup founded by veteran tech entrepreneur Naveen Jain, announced a collaboration with Microsoft to scale its molecular analysis platform — part of what Viome describes as a new era of AI-powered preventive health and wellness. Viome says Microsoft's cloud and AI infrastructure — specially tuned for its purposes in conjunction with the tech giant — will allow it to process biological data more efficiently. The idea is to expand access, reduce costs, and accelerate data processing and diagnostics. For Jain, it's a full-circle moment. Before founding such companies as InfoSpace, Intelius, and Moon Express, he was a Microsoft group manager in the 1980s and '90s, working on the business side of MSN while current Microsoft CEO Satya Nadella ran engineering for Microsoft's online division. 'Satya will someday be known as being one of the best CEOs in human history,' Jain said, using some of his trademark exuberance to describe Viome's work with the tech giant. 'He has changed Microsoft to be a company that's an unbelievably great partner.' Their collaboration addresses a massive scaling challenge. Viome says it has data from more than 1 million samples (including blood, saliva, and stool) from people in 106 countries, generating what it calls an unprecedented set of more than 10 quadrillion biological data points. Processing this data requires large memory footprints and high-speed storage, rather than the GPU-heavy computing more typical of everyday AI workloads. That difference is what drove the Microsoft collaboration, said Guru Banavar, Viome's CTO and head of AI, who previously led the team that built the foundational AI platform for IBM's Watson. Guru Banavar, Viome's CTO and head of AI. (Viome Photo) The underlying architecture developed by Microsoft and Viome 'was put together specifically to handle this type of bioinformatics with a very large-scale catalog, with a large-scale data set that's being transferred back and forth,' Banavar said. Other life sciences companies on Microsoft's Azure cloud and AI platform may also now benefit from this work, but Banavar said their early collaboration gives Viome a strategic advantage. The Bellevue, Wash.-based company's platform analyzes how genes and microbes in the body are actively functioning in real time, not just which ones are present in the body. Viome then uses that data to generate personalized health insights and recommendations. Viome does this by focusing on RNA, which plays a key role in how genes are expressed and regulated, rather than DNA, which serves as the body's more static genetic blueprint. The long-term idea is to create what it calls 'biological digital twins' — computer models that can predict how individuals will respond to specific foods and interventions. Viome is straddling the line between consumer wellness and clinical diagnostics as it looks to address issues ranging from depression to early-stage oral cancer. On the consumer side, it offers testing kits for saliva, blood and stool samples, with prices currently ranging from $229 to $299. Customers collect the samples at home and send them to Viome's lab for analysis. Results include personalized diet and nutrition insights, with options to subscribe to supplements and oral care products ranging from $79 to $199 a month. These offerings fall under the wellness category and are generally not subject to FDA regulation. According to Jain, Viome distinguishes itself in the wellness space by conducting blinded, placebo-controlled studies to validate its recommendations, publishing in peer-reviewed journals. A Viome testing kit and the company's app. (Viome Photo) The rise of AI and molecular analysis has led to a boom in competition in the personalized health sector, with companies like Thorne, ZOE, BIOHM and others offering various approaches to microbiome testing and wellness insights. At the same time, Viome has developed diagnostic tools that analyze RNA biomarkers to detect disease — including a test for early detection of oral cancer that has received FDA breakthrough device designation. That designation is designed to speed the review of promising technologies, but it is not equivalent to full FDA clearance or approval. Jain said he was inspired to start the company after his late father was diagnosed with pancreatic cancer. The experience led him to question why people develop chronic conditions, and whether diseases like cancer, diabetes and heart disease could be prevented by detecting earlier biological changes. The company's technology originated from a biodefense project at Los Alamos National Laboratory. This was an outgrowth of an approach Jain started pursuing in 2015 with his company BlueDot, aiming to commercialize scientific breakthroughs from institutions like Los Alamos and Oak Ridge National Laboratories. Founded in 2016, Viome has raised $225 million in total funding from investors including Khosla Ventures, Bold Capital, West River Group, Marc Benioff, Ezaki Glico, and Jain himself. Viome now employs close to 100 people and had nearly 100% year-over-year revenue growth, according to Jain, who declined to provide specific financials. Most customers, he said, not only take the tests but also subscribe to personalized nutrition products.
